Management of Pulmonary Arterial Hypertension in the Neonatal Unit

被引:11
|
作者
Krishnan, Usha [1 ]
机构
[1] New York Med Coll, Dept Pediat Cardiol, Valhalla, NY 10595 USA
关键词
pulmonary hypertension; persistent pulmonary hypertension in the newborn; chronic lung disease of infancy; sildenafil; bosentan; CHRONIC LUNG-DISEASE; NITRIC-OXIDE; SILDENAFIL; NEWBORN; PATHOGENESIS; DIAGNOSIS; CHILDREN; INFANTS; GROWTH; INJURY;
D O I
10.1097/CRD.0b013e3181ce9edb
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
This review article discusses the pathophysiology and management of pulmonary hypertension (PH) in the newborn unit. The discussion revolves around 2 aspects: persistent pulmonary hypertension in the newborn, which is seen in the first few weeks of life, and PH associated with chronic lung disease in the post neonatal period of infancy. Although the etiopathogenesis as well as prognosis for infantile PH differ from older children and adults, the basic principles of management are similar. Inhaled nitric oxide, intravenous prostacyclin and its analogs, and oral medications like sildenafil and endothelin receptor blockers play a very important role in PH management in the newborn unit, in addition to ventilation strategies and acid-based balance management.
引用
收藏
页码:73 / 75
页数:3
相关论文
共 50 条
  • [41] Addition of sildenafil to bosentan monotherapy in pulmonary arterial hypertension
    Mathai, S. C.
    Girgis, R. E.
    Fisher, M. R.
    Champion, H. C.
    Housten-Harris, T.
    Zaiman, A.
    Hassoun, P. M.
    EUROPEAN RESPIRATORY JOURNAL, 2007, 29 (03) : 469 - 475
  • [42] Drug Interactions Associated With Therapies for Pulmonary Arterial Hypertension
    Narechania, Shraddha
    Malesker, Mark A.
    JOURNAL OF PHARMACY TECHNOLOGY, 2022, 38 (06) : 349 - 359
  • [43] Ambrisentan: a review of its use in pulmonary arterial hypertension
    Rivera-Lebron, Belinda N.
    Risbano, Michael G.
    THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE, 2017, 11 (06) : 233 - 244
  • [44] Pharmacogenomics in the Management of Pulmonary Arterial Hypertension: Current Perspectives
    Coons, James C.
    Empey, Philip
    PHARMACOGENOMICS & PERSONALIZED MEDICINE, 2023, 16 : 729 - 737
  • [45] Initial Experience With Tadalafil in Pediatric Pulmonary Arterial Hypertension
    Takatsuki, Shinichi
    Calderbank, Michelle
    Ivy, David Dunbar
    PEDIATRIC CARDIOLOGY, 2012, 33 (05) : 683 - 688
  • [46] Phosphodiesterase Type 5 Inhibitors in Pulmonary Arterial Hypertension
    Montani, David
    Chaumais, Marie-Camille
    Savale, Laurent
    Natali, Delphine
    Price, Laura C.
    Jais, Xavier
    Humbert, Marc
    Simonneau, Gerald
    Sitbon, Olivier
    ADVANCES IN THERAPY, 2009, 26 (09) : 813 - 825
  • [47] A Review of Sildenafil in the Treatment of Pediatric Pulmonary Arterial Hypertension
    Krishnan, Usha
    Lovig, Leif
    CLINICAL MEDICINE INSIGHTS-THERAPEUTICS, 2009, 1 : 1329 - 1333
  • [48] Endothelin Receptor Antagonists for Pulmonary Arterial Hypertension: An Overview
    Raja, Shahzad G.
    CARDIOVASCULAR THERAPEUTICS, 2010, 28 (05) : e65 - e71
  • [49] Current management of pulmonary arterial hypertension
    Yerly, Patrick
    Prella, Maura
    Aubert, John-David
    SWISS MEDICAL WEEKLY, 2016, 146 : w14305
  • [50] Evaluation and management of pulmonary arterial hypertension
    Beshay, Sarah
    Sahay, Sandeep
    Humbert, Marc
    RESPIRATORY MEDICINE, 2020, 171